Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN…

Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary

Emergex uniquely develops novel 100% synthetic set-point T cell priming vaccines to address some of the worlds most pathogenic infectious diseases

Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can be rapidly developed and deployed

Abingdon, UK, 1 September 2020 Emergex Vaccines Holding Limited (Emergex), a company tackling major global infectious disease threats through the development of synthetic set point vaccines which prime the T cell immune response, today announces that it has significantly strengthened its technology platform and formed US subsidiary, Emergex USA, by acquiring the laboratories, technology and assets of US-based biotech ImmProNano Inc. Financial details of the transaction were not disclosed.

ImmProNano (IPN), based in Doylestown, PA is a specialist contract research organization in the field of Human Leukocyte Antigen T cell immunology and immunoproteomics, utilizing state of the art mass-spectrometry to determine Class I major histocompatibility complex expression libraries of viral infected cells. These libraries are critical to the development of vaccines to high pathogen viruses and intracellular bacteria. IPN also has unparalleled expertise in the T cell immunology of infectious disease and T cell vaccine development.

IPN has completed all pre-clinical testing in animals and ex vivo human samples for Emergexs recent vaccine programs including Francisella tularensis, Yellow fever, Zika, Dengue, Influenza and COVID-19.

ImmProNanos laboratory facilities and key employees will now form Emergexs US subsidiary. The team will continue to work closely with Emergexs state of the art UK R&D facility and also form critical interactions with Emergexs other vaccine collaborators at George Mason University, USA and the Institute of Molecular and Cell Biology of Singapore (A*STAR).

Storme Moore-Thornicroft, co-founder and COO of Emergex, commented: ImmProNano has been a trusted partner for several years, their deep expertise in T cell immunology complementing our novel approach to vaccine development. This acquisition establishes a US base and brings together key elements of the vaccine development process in-house, an important next step as we look to advance promising vaccine candidates in areas including Dengue Fever, pandemic flu and other globally important infectious diseases. The critical need for the ability to develop and manufacture potent vaccines in a timely and cost-effective manner has never been clearer and todays agreement ensures Emergex is well placed to meet this goal.

Originally posted here:
Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN...

What sewage can tell us about the spread of COVID-19 – High Country News

The sewer is the last stop for Bozeman, Montanas waste, but lately, its the first one for Blake Wiedenhefts work. An associate professor of microbiology and immunology at Montana State University, Wiedenheft has joined other virologists, epidemiologists and immunologists as a member of the universitys COVID-19 task force.

Back in March, a colleague mentioned testing wastewater for evidence of COVID-19 in human waste. The next day, Wiedenheft drove down to Bozemans wastewater treatment plant to see if he could grab a sample. Given how few cases there were in the area at the time, and that 6 million gallons of water flow through the plant daily, he wasnt sure if the virus would be detectable. But Wiedenheft immediately found evidence of it and it kept appearing in the four samples he analyzed over the next 10 days. Wiedenheft worked with local officials to continue regular testing as Bozeman became one of the first cities in the world to look to sewage for answers. Now, cities across the Western United States are sampling wastewater for evidence of SARS-CoV-2 as a potential early warning system for outbreaks. Scientists estimate that up to45% of people infected with the virus show no symptoms. Given that asymptomatic people are less likely to get tested, many cases may go undetected. With many areas experiencing substantial delays in swab test results, daily wastewater testing can give scientists an idea of community infection nearly immediately, Wiedenheft said.

City of Bozeman Wastewater Pre-treatment Coordinator Mark DeWald, left, and Water Reclamation Facility Lab Foreman Josh French, right, separate the housing unit of an autosampler to collect a wastewater sample jug from a Montana State University sewage line collection site.

The autosampler looks like two mini fridges stacked vertically. The top compartment houses a tube and pump, which hoovers up half-cup samples and deposits them into a plastic jug in the cool bottom compartment. Every 24 hours, a sample from this jug is taken to Wiedenhefts lab for testing. Wiedenhefts lab employs the same methods used to analyze COVID-19 nose swab tests: Researchers take RNA whether floating in a liter of wastewater or smeared on a swab and perform a procedure that amplifies the genetic signature of the SARS-CoV-2 virus. That allows researchers to identify the virus.

The challenge of analyzing wastewater, as opposed to a swab, is that RNA samples are such a tiny part of the overall jug of wastewater. Imagine youve got a jar full of jelly beans, and youre dipping into the jar to see if you can find a red jelly bean, said Wiedenheft. If your jar is small, its more likely youre going to scoop up that red jelly bean, but if your jar is big, its less likely, and youre going to have to collect more of the sample to find it. The virus is like the red jelly bean; to get an accurate glimpse into how much virus is in a citys water, scientists have to make sure the samples they collect are representative of its overall water flow. That means taking more frequent samples at peak times in the mornings, when people are starting their routines, or in the evenings, when they are doing chores as well as less frequent samples when the water flow is lower, as it is very early in the morning. Bozemans autosampler collects around three dozen samples daily.

Blake Wiedenheft, associate professor of microbiology and immunology at Montana State University and a member of the universitys COVID-19 task force. Wiedenheft has been working with the City of Bozeman Water Reclamation Facility to monitor the virus.

The upshot of Wiedenhefts lab analyses whether samples are virus positive or negative are posted on the countys public health website. In the 26 samples taken between June and mid-August, the coronavirus was detected every time.

French said they are now experimenting with sampling from specific areas of town, like the hospital and Montana States campus. Engineers have identified their main sewer flow lines and placed mobile samplers just beneath manhole covers, where they collect samples one day a week. As the school year kicks off, MSUs data could track viral spread on campus, while the hospital data could help scientists better understand how their results map on to community spread. We know how much viral protein (Wiedenheft) is detecting in his lab, but how many individuals is that reflective of? asked French.

Researchers have yet to arrive at a definitive answer. Converting wastewater data into an estimate of positive cases requires a key metric scientists are still learning about: how much virus a sick person sheds. That depends on the stage of illness the person is in, as well as how severe the illness is. Because those variables are hard to nail down, Wiedenheft has intentionally avoided reporting such estimates. We dont feel confident enough to make that translation, he said.

But in some cities, officials have released estimates using wastewater data to indicate how many community members are infected. For instance, analyses by Biobot, a wastewater testing startup, estimated that levels of SARS-CoV-2 found in Moscow, Idahos sewage corresponded to 1,800 cases. At the time of the estimate, Latah County, where Moscow is located, had only 46 known cases. (Biobot declined to be interviewed, and its hired communications firm did not answer questions about how the company calculates case estimates. A recent study published by Biobots co-founders and colleagues reported that assumptions about individuals viral load can massively affect these estimates. According to their calculations, assuming infected people have a low viral load leads to an estimate that 5% of the population is infected, whereas assuming a high viral load will lower that estimate to 0.1%.)

It was somewhat reassuring to have another backstop indicator of what was happening.

So far, many local officials have looked to wastewater analyses more as a way to corroborate their knowledge about community viral spread than as a way to estimate case numbers. We wont know how many people in the community have COVID-19 from the methodology, but this data will tell us if trends are going up or down, says Nicole Rowan, clean water program manager at the Colorado Department of Public Health and Environment, which has launched a state-wide wastewater testing effort.

Matt Kelley, health officer at the Gallatin City-County Health Department, said that when his county went through a period of few cases in May, the sewage data gave additional confirmation that spread had slowed. It was somewhat reassuring to have another backstop indicator of what was happening, he said and when positive COVID-19 swab tests rose again, so did levels of SARS-CoV-2 in the water. Kelley said that once cases fall again, it will be helpful to track wastewater as an indicator of undetected community spread. If were not seeing tests in the traditional medical testing, and also not seeing them in the wastewater, thats a validating factor for us.

Ardem Nemudryi, a postdoctoral researcher at Montana State University, uses a bottle top filter to separate SARS-CoV-2 virus RNA from a waste water sample.

As more areas launch wastewater tracking programs, Wiedenheft said theres still one thing needed: a central repository for this data, which could provide a bigger-picture view of viral spread. Over the last few months, Montana has developed several monitoring sites, and some states, like California, Colorado and Wyoming, created their own networks. Its difficult just to compile a list of cities conducting testing, since some key data is private; Biobot said it is working with 400 facilities, but declined to provide additional information, including how many cities that corresponds to. Wiedenheft points to Johns Hopkins popular coronavirus tracker as an example of a well-organized health surveillance tool. It would be nice to have a wastewater surveillance website that does the same thing, where you could look at a geographic map and look at whats happening, he said.

Stay up to date on the West with our free newsletter

Thank you for signing up for our Newsletter.

In mid-August, the U.S. Centers for Disease Control and Department of Health and Human Services announced plans for a National Wastewater Surveillance System, a portal to which health departments can submit their wastewater data. After the federal governments changes to a portal tracking hospital data lead to widespread reporting delays and data inconsistencies, its unclear how the database will fare and whether this new initiative provides funding to areas conducting testing. Wiedenhefts funding goes through August, and hes unsure where the money will come from after that. If wastewater sampling is important and I think it is, since theres plenty of evidence to suggest its really the only real-time indicator in the community then it seems important to have funding to support this ongoing effort, he said. Thats imperative to be able to manage a pandemic.

Note: The section of this story on assumptions about how viral loads impact estimates of community spread has been updated to reflect that assuming a low viral load would mean 5% of the population hasSARS-CoV-2 and that a high viral load could mean as little as 0.1% are infected.

Jane C. Hu is a contributing editor for High Country News and an independent journalist who writes about science, technology and the outdoors. She lives in Seattle. Email her at [emailprotected]or submit a letter to the editor.

Read more:
What sewage can tell us about the spread of COVID-19 - High Country News

Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a consulting role for personal reasons while a search for his replacement is conducted.

With the additions of Lisa and Kevin to our team, Magenta continues to deepen our technical expertise, bolstering our strong discovery, research, development and regulatory leadership to further our goal of delivering curative immune reset to patients in need, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. We are delighted to welcome Lisa and Kevin on board and look forward to their many contributions to the Magenta mission.

As Chief Scientific Officer, Dr. Olson will provide strategic direction, oversight and execution for Magentas research and discovery efforts. This entails driving research strategy as Magenta continues to optimize its preclinical and clinical pipeline. She will join the executive team and will be a key member of the R&D leadership team.

Dr. Olson is an experienced senior-level pharmaceutical executive, with more than 20 years of experience in research and drug discovery. She comes to Magenta following 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions, including new target approval, project advancement and licensing opportunities. Under her leadership, 15 molecules advanced into clinical development, including Upadacitinib that launched last year as Rinvoq. Prior to AbbVie, she served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer, Inc. She began her career as an Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago.

Dr. Olson holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.

As Senior Vice President, Head of Regulatory and Quality, Dr. Johnson will lead Magentas global regulatory strategy for the Companys programs across multiple therapeutic areas. He will also be responsible for the oversight and accountability for all quality activities to enable Good Practice (GxP) functions across the portfolio. In this role, Dr. Johnson will provide strategic guidance and leadership to members of the R&D leadership team and the regulatory and quality teams for Magentas portfolio for all phases of product lifecycle.

Dr. Johnson bring years of regulatory, quality assurance and development leadership, coming to Magenta from Imara, Inc., where he served as Senior Vice President, Regulatory Affairs, Quality and Pharmacovigilance, leading successful requests for several regulatory designations with the U.S. Food and Drug Administration (FDA). Prior to his time at Imara, Dr. Johnson led global regulatory strategy and implementation for breakthrough therapy-designated rare disease development programs at Vtesse, later acquired by Sucampo. He also served as Director, Global Regulatory Affairs for Rare Diseases and Gene Therapies at GlaxoSmithKline, where he was part of on the international regulatory team for the European approval of the gene therapy Strimvelis for ADA-SCID, and subsequently secured Regenerative Medicine Advanced Therapy (RMAT) designation for a retinal gene therapy product.

Dr. Johnson holds a Ph.D. in Neurobiology from the University of North Carolina (UNC) School of Medicine; a Master of Business Administration from the Kenan-Flagler School of Business, UNC; and a Bachelor of Science in Chemistry from the University of South Florida.

Along with these leadership team additions, Magenta also announced today that Jason Ryan, Chief Operating and Financial Officer, will step down from that role at the end of September. He will continue to contribute to Magenta in a consulting capacity, and the Company has commenced a search for a replacement.

Jason has been a dynamic and reliable leader at Magenta since he joined us in 2019, leading finance and operations, contributing to our strategic planning efforts, and spearheading two financings during a period of significant growth, said Gardner. We are truly grateful for his contributions to the patients we seek to serve, our employees and business partners.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Read more from the original source:
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;...

$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Researchers to study how immune cells respond after lung, heart transplants

Daniel Kreisel, MD, PhD, (right) the surgical director of lung transplantation at Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital, is a principal investigator of two grants from the National Institutes of Health (NIH) totaling $10 million to study the prevention of organ rejection after transplantation. Kreisel is shown operating on a lung transplant patient with Varun Puri, MD, an associate professor of surgery and the associate surgical director of the lung transplant program.

Transplant surgeons and researchers at Washington University School of Medicine in St. Louis have received two grants totaling $10 million from the National Institutes of Health (NIH) to study how immune cells contribute to organ rejection, with the aim of improving the viability of organs after transplant.

A $7.7 million program project grant from the National Institute of Allergy and Infectious Diseases funds research to understand the immunological basis of lung transplant rejection.

And the National Heart, Lung, and Blood Institute awarded nearly $2.6 million to aid studies of the immune systems role in heart transplant rejection.

The ultimate goal is to improve the long-term outlook for lung and heart transplant patients, said Daniel Kreisel, MD, PhD, the surgical director of lung transplantation at the School of Medicine and Barnes-Jewish Hospital, and a principal investigator of both NIH grants. It is our hope that through our research, we will gain critical new insight into the immunological underpinnings of transplant tolerance and rejection.

Understanding how immune cells respond to transplanted organs sets the stage for developing novel therapeutic strategies to improve outcomes for transplant patients, said Kreisel, who is the G. Alexander Patterson, MD/Mid-America Transplant Endowed Distinguished Chair in Lung Transplantation.

For lung transplant patients, the risk of organ failure and death is particularly high. Five years after lung transplantation, about half of the lungs are still functioning, according to the U.S. Organ Procurement and Transplantation Network. This compares with five-year organ survival rates of about 70% for heart, liver and kidney transplants.

Uncovering the basis for the poor survival of lung transplant recipients should also give us new insight into the causes of other inflammatory diseases that affect the lung, said Andrew Gelman, PhD, a professor of surgery, and of immunology and pathology at Washington University and the Jacqueline G. and William E. Maritz Endowed Chair in Immunology and Oncology.

The funding will support three projects led by Kreisel, Gelman and Alexander S. Krupnick, MD, a professor of surgery and director of the lung transplant program at the University of Maryland that examine different immunological aspects of lung transplant tolerance. This refers to the ability of the immune system to recognize a transplanted lung as the bodys own.

Often, lung transplant remains the only option for patients with end-stage lung disease, a condition that can be brought on by emphysema, pulmonary fibrosis, cystic fibrosis and other lung disorders. Unlike other organs, lungs constantly are exposed to whatever is in the environment, including bacteria, viruses and air pollution. Such fragility contributes to the increased risk of chronic rejection and organ failure.

Also playing a key role in the research is Wenjun Li, MD, an associate professor of surgery and director of microsurgery in the Thoracic Immunobiology Laboratory. He is highly regarded among transplant scientists for developing microsurgical and imaging methods that have advanced the understanding of lung and heart transplantation.

For heart transplant patients, receiving a new heart is one of the most viable options for end-stage cardiovascular disease. About 3,550 people received a heart transplant from a deceased donor in 2019, according to the U.S. Organ Procurement and Transplantation Network.

However, heart transplant success can be threatened when the donor heart doesnt work properly. This complication called primary graft failure typically occurs in the early days following surgery and can prevent a newly transplanted heart from supplying enough blood to the bodys vital organs.

Current treatments have focused on targeting immune cells in the recipients heart. These have many side effects and are only modestly effective, said Kory J. Lavine, MD, PhD, a Washington University associate professor of medicine in the Cardiovascular Division and also one of the principal investigators. Our research will focus on alternative approaches based on targeting immune pathways and cell populations in the donor heart. We hope that insight gained from the research will result in new therapies that will increase donor heart availability and improve survival after heart transplantation.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the rest here:
$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis - Washington...

This Free MIT Course Has Everything You Need To Know About COVID-19 – Well+Good

The pandemic has brought a barrage of news with so much information it can be overwhelming to understand whats going on (and to understand whats false). A new free online course from the Massachusetts Institute of Technology (MIT) serves to make that easier. COVID-19, SARS-CoV-2 and the Pandemic will walk you through the science of the pandemic with the help of a few familiar experts.

This MIT COVID-19 course is taught by professors Richard Young, PhD,and Facundo Batista, PhD, and will feature weekly guest lecturers like Anthony Fauci, MD. It explains the fundamentals of coronavirus and host cell biology, immunology, epidemiology, clinical disease, and vaccine and therapeutic development. Part of the course will cover lessons from the AIDS pandemic and the ins and outs of viral immunology.

The course will take place every Tuesday from 11:30 a.m. to 12:30 p.m. ET from September 1 through December 8. The course is open to allMIT students, any eligible cross-registered students, and the general public. Though the general public can view the classes, only students registered through the university will be able to ask questions.

To watch it live, click this link and enter the password mit-covid. If you miss a class, head to this page to view a recording. And be prepared to learn from professors at the top of their game.

Dr. Young is a geneticist who explores how and why gene expression differs in healthy versus diseased cells. He received his PhD from Yale University. In 2006, Scientific American recognized him as one of the top 50 leaders in science, technology and business. Hes also won a Burroughs Wellcome Scholarship, the Chiron Corporation Biotechnology Research Award, and Yales Wilbur Cross Medal. He has served as an advisor to Science magazine, the National Institutes of Health, and the World Health Organization.

Dr. Batista is a professor of microbiology and immunology at Harvard Medical School and the associate director of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. He received his PhD from the International School of Advanced Studies in Trieste, Italy. He has served on the editorial boards of various journals, including Science. He is also the recipient of the Royal Society Wolfson Research Merit Award and a fellow of the UK Academy of Medical Sciences. In 2018, he was elected a fellow of the American Academy of Microbiology.

According to the syllabus, the course will cover:

Dr. Fauci will be a guest lecturer at the class covering the Insights from the COVID-19 pandemic on September 22. Dr. Fauci has served as the director of the National Institute of Allergy and Infectious Disease since 1984. He oversees an extensive portfolio of research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis, and malaria.

Additional guest faculty include: Nobel laureate and biologist David Baltimore, PhD; neurosurgeon Victoria Clark, MD, PhD; immunologist Kizzmekia Corbett, PhD; biologist Britt Glaunsinger, PhD; immunobiologist Akiko Iwasaki, PhD; geneticist, molecular biologist, and mathematician Eric Lander, PhD; epidemiologist Michael Mina, PhD; molecular immunologist Michel Nussenzweig, MD, PhD; Shiv Pillai, MD, PhD; immunologist Arlene Sharp MD, PhD; immunologist Skip Virgin MD, PhD; and internal and infectious disease physician Bruce Walker, MD, PhD.

Excerpt from:
This Free MIT Course Has Everything You Need To Know About COVID-19 - Well+Good

Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham – University of Birmingham

The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

A new test to detect COVID-19 antibodies in people with mild symptoms has been launched by The Binding Site in collaboration with the University of Birmingham's Clinical Immunology Service

The unique SARS-CoV-2 Antibody ELISA has been developed to identify individuals who have had a mild, non-hospitalised disease course following SARS-CoV-2 exposure. This latest development has brought together the Binding Site's extensive experience in developing highly precise, accurate blood tests with the expertise of leading immunology and immunity experts at the University of Birmingham

The new test specifically detects antibodies (IgG, IgA and IgM) to the SARS-CoV-2 trimeric spike protein, which is an important protein for the virus infectivity. The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

Professor Adam Cunningham, Professor of Functional Immunity at the University of Birmingham explains: Humans make three types of antibodies Anti-IgM, IgG and IgA. IgM tends to appear first, and IgG and lgA tend to appear later. By combining all three The Binding Site test is able to detect COVID-19 infection in people who have only mild symptoms of the disease.

The CE-marked ELISA test is simple to use and provides up to 93 test results in 60-90 minutes. The collaboration has shown that as well as through saliva or venous blood samples, the test can also detect antibodies in a dried blood spot. This means that the test can be developed into a finger prick test for home use, offering a more accurate testing capability in homes, businesses, airports as well as GP surgeries and hospitals in the UK and worldwide including low and middle income countries

Dr Stephen Harding, Chief Scientific Officer at The Binding Site said: We set out to develop a test with the University of Birmingham that would detect COVID-19 early, and validated the test in a non-hospitalised population that had mild symptoms which is the largest target population for COVID-19 testing - and we designed the testing kit so it can be used by any laboratory in the world.

The test was developed using over 800 blood samples taken from people who had mild to moderate disease. The test is already being used in many of the clinical studies conducted through the University of Birmingham including those focused on health care workers.

Charles de Rohan, CEO of The Binding Site, commented: The long-standing partnership with the University of Birmingham has brought together unrivalled academic, clinical and commercial expertise, and the combined team worked together seamlessly and quickly to deliver this unique and forward thinking test in record time.

Professor Alex Richter, Professor of Clinical Immunology at the University of Birmingham, who led the test development team, commented: There are two things to get right in an antibody test - which antibodies are we looking for, and what are they recognising? Testing for IgM, IgG and IgA antibodies to the spike protein should give an advantage in terms of early and accurate detection of people with recent exposure, who are not showing symptoms.

The Binding Site has provided free kits to support work in developing countries where the disease continues to spread quickly and is impacting on children through Paediatric Multisystem Inflammatory Syndrome (PIMS). The test has been submitted for rapid FDA approval and is expected to be available in quantities of over 2 million tests per month.

For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.

To hear more about the project please follow this link towatch a video

About the University of Birmingham

The University of Birmingham is ranked amongst the worlds top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.

About The Binding Site

Binding Site leads the way in specialist protein diagnostics. Built on strong scientific foundations with extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

The facility in Birmingham, UK, is their global headquarters, employing over 750 of its 1,100 total staff and housing all product development, manufacturing, global distribution and marketing. The Binding Site has a direct presence in over 25 countries and product sales through business partners in more than 100 countries.

Excerpt from:
Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham - University of Birmingham

Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing – GlobeNewswire

TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they will provide COVID-19 testing to hundreds of thousands of students across approximately 1600 locations as they return to school in September and over the next several months. Fulgent will provide its FDA EUA-approved at-home test, Picture by Fulgent, a RT-PCR test that provides the highest level of sensitivity and specificity, utilizing a self-collected nasal swab sample. Fulgent will provide results within 24-48 hours from the time when Fulgent receives and accepts a specimen for the test.

Fulgent is very happy to partner with the City of New York on such an important and novel testing protocol. Its an ambitious goal to test so many students in such a rapid fashion, but the combination of the Fulgent technology platform and lab capacity along with the strong testing infrastructure of New York City makes this possible, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. In just a few short days, we were able to get the first shipment of hundreds of thousands of Picture kits to New York City. We will now be working closely with the city on the distribution, return and replenishment of the kits, added Perthuis.

This is one of the first large-scale testing programs for COVID-19 to utilize an at-home test kit. Fulgents Picture Genetics at-home test was chosen due to its convenient self-administration, which can be used on-site at schools as well as at home. The companys industry-leading turnaround time of 24-48 hours also makes this a powerful tool for back-to-school testing.

About NYC Test & Trace Corps

The NYC Test & Trace Corps is a public health initiative to fight COVID-19 so that New Yorkers can get back to school, work and help New York City reopen safely. The Corps is a group of doctors, public health professionals and community advocates working to reverse the COVID-19 outbreak and protect our city. The public health program is led by NYC Health + Hospitals in close collaboration with the NYC Department of Health and Mental Hygiene and other city agencies. Through its robust and citywide partnerships, The Corps helps New Yorkers receive free, safe and confidential testing for COVID-19 and for the antibody test. It ensures that anyone with the virus receives care and can safely isolate to prevent the spread. For more information, visit https://www.nychealthandhospitals.org/test-and-trace/.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The Company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.comfor more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; expected future lab capacity and turnaround times; expectations or guidance regarding future revenues and managements judgements and evaluations of the companys platform and technology.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Excerpt from:
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing - GlobeNewswire

Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years – Yahoo Finance

When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really flourishing, you can make more than 100%. Long term Seattle Genetics, Inc. (NASDAQ:SGEN) shareholders would be well aware of this, since the stock is up 272% in five years. Then again, the 9.1% share price decline hasn't been so fun for shareholders.

See our latest analysis for Seattle Genetics

Given that Seattle Genetics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

For the last half decade, Seattle Genetics can boast revenue growth at a rate of 24% per year. Even measured against other revenue-focussed companies, that's a good result. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 30% per year, compound, during the period. So it seems likely that buyers have paid attention to the strong revenue growth. To our minds that makes Seattle Genetics worth investigating - it may have its best days ahead.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth

Seattle Genetics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So we recommend checking out this free report showing consensus forecasts

We're pleased to report that Seattle Genetics shareholders have received a total shareholder return of 115% over one year. That's better than the annualised return of 30% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Seattle Genetics .

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

See the original post:
Introducing Seattle Genetics (NASDAQ:SGEN), The Stock That Zoomed 272% In The Last Five Years - Yahoo Finance

Merck Foundation and 13 African First Ladies meet to Strengthen Healthcare to control COVID 19 – Outlook India

(Eds: Disclaimer: The following press release comes to you under an arrangement with Business Wire India. PTI takes no editorial responsibility for the same.) Mumbai, Maharashtra, India & Cape Town, South Africa Business Wire IndiaMerck Foundation, the philanthropic arm of Merck KGaA Germany conducted their first Video Conference Summit of Merck Foundation First Ladies Initiative (MFFLI) on 31st August 2020 to define and follow up on different joint programs that aims to advance public healthcare sector capacity and strengthen the response to COVID 19 in their countries. The MFFLI VC Summit 2020 was hosted by Prof. Dr. Frank Stangenberg Haverkamp, Chairman of the Executive Board of E. Merck KG and the Chairman of Merck Foundation Board of Trustees and Dr. Rasha Kelej, CEO of Merck Foundation and President, Merck More Than a Mother and One of 100 Most Influential African (2019 & 2020) and attended by 13 African First Ladies, who are Ambassadors of Merck More than a Mother; H.E. AUXILLIA MNANGAGWA, The First Lady of Zimbabwe; H.E. ESTHER LUNGU, The First Lady of Zambia; H.E. FATIMA MAADA BIO, The First Lady of Sierra Leone; H.E. ASSATA ISSOUFOU MAHAMADOU, The First Lady of Niger; H.E. MONICA GEINGOS, The First Lady of Namibia; H.E. ISAURA FERRO NYUSI, The First Lady of Mozambique; H.E. MONICA CHAKWERA, The First Lady of Malawi; H.E. REBECCA AKUFO-ADDO, The First Lady of Ghana; H. E. FATOUMATTA BAHBARROW, The First Lady of The Gambia; H.E. BRIGITTE TOUADERA, The First Lady of Central African Republic; H.E. ANGELINE NDAYISHIMIYE, The First Lady of Burundi; H.E. NEO JANE MASISI, The First Lady of Botswana; H.E. ANA DIAS LOURENO, The First Lady of Angola. Prof. Dr. Frank Stangenberg Haverkamp, Chairman of the Executive Board of E. Merck KG and the Chairman of Merck Foundation Board of Trustees emphasized, The effects of the COVID-19 pandemic have been greater than many expected across the globe. The pandemic has highlighted the importance of investing in improving access to equitable and quality healthcare which is Merck Foundation''s strategy since 2012, even before the pandemic started. Dr. Rasha Kelej, CEO of Merck Foundation explained, I am very proud of our valuable partnership with the African First ladies as Merck more than a Mother Ambassadors. We have always believed in the importance of building healthcare capacity through providing training to healthcare providers in many medical specialties. This has been our strategy since we started in 2012 in partnership with African First Ladies and Ministries of Health, much before the pandemic started. As a response to COVID 19 pandemic, we adopted online medical education strategy through providing more than 350 African doctors with one-year online diploma and two-year online master degree in many specialties such as: Respiratory Medicines and Acute medicines, Diabetes, Cardiology, Endocrinology, and Sexual and Reproductive Medicines. This is in addition to more than 500 African and Asian doctors who benefited from our original clinical training programs in Diabetes & Cardiovascular, Oncology, Fertility specialists, and embryology in India, Egypt, Kenya and Malaysia which will resume after the lockdown ends. The MFFLI VC Summit, special edition aims to share experiences, discuss challenges, and define solutions to further strengthen healthcare capacity to better respond to this global pandemic in Africa. The African First Ladies shared the experiences of working closely with Merck Foundation in their respective countries with special focus on the programs to build healthcare capacity and the response to COVID -19. H.E. AUXILLIA MNANGAGWA, The First Lady of Zimbabwe & Ambassador of Merck More Than a Mother emphasized, I am very happy to see Merck Foundations strong commitment to advance the public healthcare sector across Africa. This is very critical to Zimbabwe, in the light of current pressure on our healthcare sector. More than 117 local doctors are enrolled in these training programs which will transform our healthcare sector. H.E. ESTHER LUNGU, First Lady of Zambia & Ambassador of Merck More Than a Mother emphasized, We are proud of our partnership with Merck Foundation, which started in 2019. In a very short period, we have been able to reshape the healthcare landscape of Zambia by providing our doctors and nurses with specialty training in the fields of Cancer, Diabetes, Cardiology, Endocrinology, Respiratory, Acute medicines, Sexual and Reproductive medicines, Fertility and Embryology. All of these fields are very critical and were lacking in our country. This will contribute to our battle against coronavirus and other diseases. H.E. FATIMA MAADA BIO, The First Lady of Sierra Leone & Ambassador of Merck More Than a Mother expressed, I am extremely elated with our partnership with Merck Foundation, as together, we are making history in Sierra Leone by providing training for the First Oncologists in the country to establish the first skilled cancer care team. Also, our doctors are being trained in the fields of diabetes and fertility care. We will scale up the program to more fields together with Merck Foundation very soon. H.E. ASSATA ISSOUFOU MAHAMADOU, The First Lady of Niger & Ambassador of Merck More Than a Mother emphasized, I am happy to be part of this prestigious platform. Since the Merck Foundation launch in 2017, together we have made a significant impact on our healthcare sector, through establishing a strong platform of Health experts in very critical fields such as; Diabetes, Oncology and Fertility care in Niger. H.E. MONICA GEINGOS, The First Lady of Namibia & Ambassador of Merck More Than a Mother said, I am very happy to see that Merck Foundation is strongly committed to advancing the public healthcare sector across Africa. This is very critical to our countries in light of the current medical and public concerns. This is very important for Namibia as we have a very limited number of local specialists in the public sector, we are very happy to enroll 21 Namibian doctors in online diplomas in many fields, including 8 in sexual and reproductive medicines which is very important for women health. H.E. Dr. ISAURA FERRO NYUSI, The First Lady of Mozambique & Ambassador of Merck More Than a Mother explained, Together with Merck Foundation, I am fully committed to will work closely to introduce innovative ideas that will engage different sectors to create a culture shift with the aim to break the stigma of infertility and make a great impact in a short time. H.E. MONICA CHAKWERA, The First Lady of Malawi & Ambassador of Merck More Than a Mother said, I am looking forward to starting our important long term partnership with Merck Foundation. I am willing to capitalize on the valuable programs of Merck Foundation, by scaling them up nationwide to contribute to the social and economic development of Malawi. H.E. REBECCA AKUFO-ADDO, The First Lady of Ghana & Ambassador of Merck More Than a Mother elaborated, We launched the innovative programs of Merck Foundation at the beginning of 2019, to build healthcare capacity and break the infertility stigma. To share with you that since then and in a very short time we have been able to provide and enroll many of our healthcare providers with specialty training in the fields of Cancer, Diabetes, Cardiology, Endocrinology, Respiratory, Acute medicines, Sexual and Reproductive medicines, Fertility specialists and Embryology training. H.E. FATOUMATTA BAHBARROW, The First Lady of The Gambia & Ambassador of Merck More Than a Mother said, I am delighted to share the magnificent outcomes of my long term partnership with Merck Foundation. Together we have been able to empower infertile women through access to information, education, health, and change of mindset. Also, we have enrolled 25 Gambian doctors in One-year online diploma and one-year master degree in many medical specialties. H.E. BRIGITTE TOUADERA, The First Lady of Central African Republic & Ambassador of Merck More Than a Mother emphasized, I am very proud to work closely with Merck Foundation to advance healthcare sector and empower infertile women in my country. We also initiated in my country, an important project Empowering Berna where we established small businesses for infertile women and train them to run their businesses so they can have income and become independent. Their lives have been transformed since then. H.E. ANGELINE NDAYISHIMIYE, The First Lady of Burundi & Ambassador of Merck More Than a Mother expressed, I am very happy to be appointed the Ambassador of Merck More Than a Mother last week. I am excited about the work that has been done in my country so far and looking forward to taking this partnership to new heights. H.E. NEO JANE MASISI The First Lady of Botswana & Ambassador of Merck More Than a Mother highlighted, Merck Foundations strategy of building healthcare capacity is more relevant now than ever. More than 34 doctors were enrolled to different specialties, I will closely work with Merck Foundation and our Ministry of Health to ensure the success of this program to be able to improve our peoples health and wellbeing. H.E. ANA DIAS LOURENO, The First Lady of Angola expressed, I am very proud and happy to be a part of MFFLI VC Summit and look forward to a long-term partnership with Merck Foundation. We will closely work together on all their initiatives to build healthcare capacity and empower girls in education.About Merck Foundation First Ladies Initiative Summit MFFLIMFFLI is a Merck Foundation platform of African First Ladies and Merck More Than a Mother Ambassadors established with the aim to discuss challenges, define solutions, measure impact and share experience to ensure continuous improvement and exchange variable aspects of different cultures in order to localize and/or standardize specific messages that can raise awareness and create a culture shift across Africa with regards to the below objectives: Breaking the Stigma around infertile couples in general and infertile women in particular. Empowering Girls and Women in Education in general and in STEM in particular. Improving access to quality & equitable healthcare solutions.To View the Image Click on the Link Below:Merck Foundation First Ladies Initiative - VC Summit 2020 PWRPWR

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI

Read more from the original source:
Merck Foundation and 13 African First Ladies meet to Strengthen Healthcare to control COVID 19 - Outlook India